Compounds > lp533401
Page last updated: 2024-11-13

lp533401

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LP533401: Serotonin Agents; Tryptophan Hydroxylase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44560455
CHEMBL ID511275
SCHEMBL ID307901
MeSH IDM0544978

Synonyms (19)

Synonym
bdbm50019143
CHEMBL511275 ,
SCHEMBL307901
(2s)-2-amino-3-(4-(2-amino-6-(2,2,2-trifluoro-1-(3'-fluorobiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid
CS-7843
lp-533401
HY-15849
lp533401
BCP19309
lp 533401;lp-533401
lp 533401
945976-43-2
(2s)-2-amino-3-(4-(2-amino-6-(2,2,2-trifluoro-1-(3'-fluoro-[1,1'-biphenyl]-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid
(2s)-2-amino-3-[4-[2-amino-6-[2,2,2-trifluoro-1-[4-(3-fluorophenyl)phenyl]ethoxy]pyrimidin-4-yl]phenyl]propanoic acid
lp-533401 (free base)
MS-29740
gtpl11405
VMB97643
AKOS040741971

Research Excerpts

Overview

LP533401 is an orally bioavailable small molecule. It inhibits tryptophan hydroxylase-1, an enzyme responsible for the synthesis of gut-derived serotonin (GDS)

ExcerptReferenceRelevance
"LP533401 is an inhibitor of peripheral serotonin synthesis."( Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401.
Cylwik, B; Domaniewski, T; Kalaska, B; Mor, A; Pawlak, D; Pawlak, K; Sieklucka, B; Zieminska, M, 2020)		1.47
"LP533401 is an orally bioavailable small molecule that inhibits tryptophan hydroxylase-1, an enzyme responsible for the synthesis of gut-derived serotonin (GDS). "( LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys.
Domaniewski, T; Doroszko, M; Grabowski, P; Kalaska, B; Lipowicz, P; Pawlak, D; Pawlak, K; Zawadzki, R; Znorko, B; Łebkowska, U, 2018)		3.37
"LP533401 is an inhibitor of tryptophan hydroxylase 1, which regulates serotonin production in the gut. "( The effect of an inhibitor of gut serotonin (LP533401) during the induction of periodontal disease.
Anbinder, AL; Corazza, BJ; de Oliveira, FE; de Oliveira, LD; Elefteriou, F; Franco, GC; Lima, GM; Moraes, RM; Perrien, DS, 2016)		2.14

Treatment

LP533401 or citalopram treatment partially prevented PH development in wild-type mice exposed to chronic hypoxia. Treatment with LP533 401 decreased serotonin turnover and restored bone mineral status, microarchitecture, and strength in CKD rats.

ExcerptReferenceRelevance
"LP533401 or citalopram treatment partially prevented PH development in wild-type mice exposed to chronic hypoxia."( Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice.
Abid, S; Adnot, S; Amsellem, V; Chevarin, C; Dubois-Randé, JL; Gary-Bobo, G; Hamon, M; Houssaini, A; Marcos, E; Mouraret, N; Tissot, CM; Wan, F, 2012)		1.1
"Treatment with LP533401 decreased serotonin turnover and restored bone mineral status, microarchitecture, and strength in CKD rats to the values observed in the controls."( LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys.
Domaniewski, T; Doroszko, M; Grabowski, P; Kalaska, B; Lipowicz, P; Pawlak, D; Pawlak, K; Zawadzki, R; Znorko, B; Łebkowska, U, 2018)		2.26
"Treatment with LP533401 and its vehicle resulted in the inhibition of transient receptor potential vanilloid receptor subtypes 5 and 6 (TRPV5, TRPV6) and calbindin (CaBP-28k, CaBP-9k) expression. "( The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats.
Domaniewski, T; Pawlak, D; Pawlak, K; Znorko, B, 2019)		1.26

Bioavailability

ExcerptReferenceRelevance
"Decreasing the bioavailability of serotonin (5-HT) by inhibiting its biosynthesis may represent a useful adjunctive treatment of pulmonary hypertension (PH)."( Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice.
Abid, S; Adnot, S; Amsellem, V; Chevarin, C; Dubois-Randé, JL; Gary-Bobo, G; Hamon, M; Houssaini, A; Marcos, E; Mouraret, N; Tissot, CM; Wan, F, 2012)		0.38
"LP533401 is an orally bioavailable small molecule that inhibits tryptophan hydroxylase-1, an enzyme responsible for the synthesis of gut-derived serotonin (GDS)."( LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys.
Domaniewski, T; Doroszko, M; Grabowski, P; Kalaska, B; Lipowicz, P; Pawlak, D; Pawlak, K; Zawadzki, R; Znorko, B; Łebkowska, U, 2018)		3.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tryptophan 5-hydroxylase 1Rattus norvegicus (Norway rat)IC50 (µMol)0.40000.03801.30806.4300AID1153781
Tryptophan 5-hydroxylase 1Homo sapiens (human)IC50 (µMol)0.58300.01600.34620.7700AID1707824
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
platelet degranulationTryptophan 5-hydroxylase 1Homo sapiens (human)
circadian rhythmTryptophan 5-hydroxylase 1Homo sapiens (human)
aromatic amino acid metabolic processTryptophan 5-hydroxylase 1Homo sapiens (human)
negative regulation of ossificationTryptophan 5-hydroxylase 1Homo sapiens (human)
response to immobilization stressTryptophan 5-hydroxylase 1Homo sapiens (human)
serotonin biosynthetic processTryptophan 5-hydroxylase 1Homo sapiens (human)
positive regulation of fat cell differentiationTryptophan 5-hydroxylase 1Homo sapiens (human)
bone remodelingTryptophan 5-hydroxylase 1Homo sapiens (human)
mammary gland alveolus developmentTryptophan 5-hydroxylase 1Homo sapiens (human)
regulation of hemostasisTryptophan 5-hydroxylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
iron ion bindingTryptophan 5-hydroxylase 1Homo sapiens (human)
protein bindingTryptophan 5-hydroxylase 1Homo sapiens (human)
tryptophan 5-monooxygenase activityTryptophan 5-hydroxylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytosolTryptophan 5-hydroxylase 1Homo sapiens (human)
neuron projectionTryptophan 5-hydroxylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID343317Drug level in C57 albino mouse brain at 10 mg/kg, po after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID1153781Inhibition of TPH-1-mediated serotonin biosynthesis in rat RBL2H3 cells after 48 hrs by RP-HPLC analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Tryptophan hydroxylase 1 (Tph-1)-targeted bone anabolic agents for osteoporosis.
AID1707822Inhibition of Tryptophan hydroxylase 1 (unknown origin) at 1 uM incubated for 4 hrs by fluorescence based assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Peripheral Selective Oxadiazolylphenyl Alanine Derivatives as Tryptophan Hydroxylase 1 Inhibitors for Obesity and Fatty Liver Disease.
AID343331Half life in C57 albino mouse at 10 mg/kg, po2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343320Reduction of 5HT level in mouse intestine at 30 mg/kg, po twice a day2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343322Reduction of 5HT level in mouse colon at 30 mg/kg, po twice a day2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343321Reduction of 5HT level in mouse intestine at 90 mg/kg, po twice a day2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343315AUC (0 to infinity) in C57 albino mouse at 1 mg/kg, iv2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343332AUC (0 to infinity) in C57 albino mouse at 10 mg/kg, po2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343311Tmax in C57 albino mouse at 10 mg/kg, po2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343309Volume of distribution at steady state in C57 albino mouse 1 mg/kg, iv2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343314AUC (0 to 24 hrs) in C57 albino mouse at 10 mg/kg, po2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID1298869Kinetic aqueous solubility in pH 7.4 50 mM phosphate buffer2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors.
AID343318Drug level in C57 albino mouse brain at 10 mg/kg, po after 6 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343310Half life in C57 albino mouse at 1 mg/kg, iv2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID1707824Inhibition of Tryptophan hydroxylase 1 (unknown origin) incubated for 4 hrs by fluorescence based assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Peripheral Selective Oxadiazolylphenyl Alanine Derivatives as Tryptophan Hydroxylase 1 Inhibitors for Obesity and Fatty Liver Disease.
AID339752Clearance in C57 albino mouse plasma at 1 mg/kg, iv2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID1298870Protein binding in rat plasma by equilibrium dialysis2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors.
AID343313AUC (0 to 6 hrs) in C57 albino mouse at 1 mg/kg, iv2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343319Drug level in C57 albino mouse brain after 24 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343330Ratio of drug level in brain to plasma in C57 albino mouse at 10 mg/kg, po after 6 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343323Reduction of 5HT level in mouse colon at 90 mg/kg, po twice a day2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343329Ratio of drug level in brain to plasma in C57 albino mouse at 10 mg/kg, po after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343316Oral bioavailability in C57 albino mouse at 10 mg/kg2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
AID343312Cmax in C57 albino mouse at 10 mg/kg, po2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (6.67)29.6817
2010's11 (73.33)24.3611
2020's3 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.87 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.34 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
kynurenine
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.. kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.		2.2510aromatic ketone;
non-proteinogenic alpha-amino acid;
substituted aniline		human metabolite
alendronate
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.		2.06101,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
buspirone
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.		2.3110azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
citalopram
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.		2.07102-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		2.2510erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
ursolic acid
[no description available]		2.110hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
3 beta-o-acetylursolic acid
[no description available]		2.110triterpenoid
telotristat
telotristat: a tryptophan hydroxylase inhibitor		2.1310phenylalanine derivative
ConditionIndicatedRelationship StrengthStudiesTrials
Cholera Infantum
[description not available]		02.0410
Age-Related Osteoporosis
[description not available]		03.940
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		03.940
Impaired Glucose Tolerance
[description not available]		02.3110
Liver Steatosis
[description not available]		02.3110
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		02.3110
Weight Gain
Increase in BODY WEIGHT over existing weight.		02.3110
Glucose Intolerance
A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.		02.3110
Chronic Kidney Diseases
[description not available]		03.1240
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.2450
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		03.1240
Low Bone Density
[description not available]		02.2510
Bone Diseases, Metabolic
Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.		02.2510
CKD-MBD
[description not available]		02.2110
Chronic Kidney Disease-Mineral and Bone Disorder
Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders.		02.2110
Uremia
A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.		02.2110
Disease Exacerbation
[description not available]		02.110
Acute Lymphoid Leukemia
[description not available]		02.110
Leucocythaemia
[description not available]		02.110
Acute Myelogenous Leukemia
[description not available]		02.110
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.110
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		02.110
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		02.110
Attachment Loss, Periodontal
[description not available]		02.1310
Parodontosis
[description not available]		02.1310
Pericementitis
[description not available]		02.1310
Alveolar Bone Atrophy
[description not available]		02.1310
Periodontal Diseases
Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.		02.1310
Periodontitis
Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)		02.1310
Bone Loss, Perimenopausal
[description not available]		02.0510
Osteoporosis, Postmenopausal
Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.		02.0510
Brittle Bone Disease
[description not available]		02.9810
Osteogenesis Imperfecta
COLLAGEN DISEASES characterized by brittle, osteoporotic, and easily fractured bones. It may also present with blue sclerae, loose joints, and imperfect dentin formation. Most types are autosomal dominant and are associated with mutations in COLLAGEN TYPE I.		02.9810
Bone Loss, Osteoclastic
[description not available]		02.0610
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.0610
Anoxemia
[description not available]		02.0710
Pulmonary Hypertension
[description not available]		02.0710
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.0710
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.		02.0710